ClinicalTrials.gg
CompletedNCT01214239Updated Aug 25, 2016Results posted

Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control

A Phase 3 interventional study of Placebo and Linagliptin in Diabetes Mellitus, Type 2, sponsored by Boehringer Ingelheim. Completed at 19 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-08-25.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 67 studies testing linagliptin in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Linagliptin · Diabetes Mellitus, Type 2.

Enrollment
23rd of 67
300 · median 175
Started
2010
with 7 others
Phase 3
31 of 67
none open now
Registered
22nd of 67
by date
Lead sponsor
36 of 67
Boehringer Ingelheim

Among the 67 studies testing linagliptin in Diabetes Mellitus, Type 2, this one is the 23rd largest by enrollment, is one of 8 that started in 2010, is one of 31 in phase 3, and was the 22nd registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 67 studies testing linagliptin in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About linagliptin

Linagliptin: first FDA approval 2011 (TRADJENTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing linagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with type 2 diabetes and insufficient glycaemic control.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients with a diagnosis of type 2 diabetes mellitus, either treatment naive or treated with one antidiabetic medication. Antidiabetic therapy has to be unchanged for 6 weeks prior to the
  2. Diagnosis of type 2 diabetes prior to informed consent
  3. Glycosylated A1 () at Visit 1a (Screening):

    For patients undergoing wash out of previous medication: HbA1c =7.0to =9.5% For patients not undergoing wash-out of previous medication: HbA1c =7.0 to =10.0%

  4. Glycosylated haemoglobin A1 (HbA1c) =7.0 to =10.0% at Visit 2 (Start of Run-in)
  5. Age = 18 and \< 80 years at Visit 1a (Screening)
  6. (Body Mass Index) = 45 kg/m2 at Visit 1a (Screening)
  7. Signed and dated written informed consent by date of Visit 1a in accordance with GCP and local legislation

Exclusion criteria

Exclusion criteria:

  1. Myocardial infarction, stroke or within 6 months prior to
  2. Impaired hepatic function, defined by serum levels of either (SGPT), Aspartate transaminase(SGOT), or alkaline phosphatase above 3 x (ULN) as determined at Visit 1a
  3. Uncontrolled hyperglycaemia with a glucose level >240 mg/dl (>13.3 mmol/L) after an overnight fast during wash-out / placebo run-in and confirmed by a second measurement (not on the same day)
  4. Known or allergy to the product or its
  5. Treatment with more than one antidiabetic drug within 6 weeks prior to informed consent
  6. Treatment with rosiglitazone or pioglitazone within 3 months prior to informed consent
  7. Treatment with Glucagon-like peptide 1(GLP-1) analogues (e.g. exenatide) , Dipeptidyl-Peptidase 4(DPP-IV) inhibitor within 3 months prior to informed consent
  8. Treatment with insulin within 3 months prior to informed consent
  9. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat, rimonabant) within 3 months prior to informed consent
  10. Alcohol abuse within the 3 months prior to informed consent that would interfere with trial participation or drug abuse
  11. Participation in another trial with an investigational drug within 2 months prior to informed consent
  12. Pre-menopausal women (last menstruation = 1 year prior to informed consent) who:

    • are nursing or pregnant,
    • or are of and are not practicing an acceptable method of , or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include transdermal patch, intra-uterine devices/systems (IUDs/IUSs), oral, implantable or injectable contraceptives, sexual abstinence and vasectomised partner. No exception will be made.
  13. Current treatment with systemic at time of informed consent or change in dosage of thyroid hormones within 6 weeks prior to informed consent.
  14. Renal failure or renal impairment (serum creatinine =1.5 mg/dl as determined at Visit 1a)
  15. Dehydration by clinical judgement of the investigator
  16. Unstable or acute congestive heart failure
  17. Acute or chronic metabolic acidosis (present in patient history)
  18. Hereditary galactose intolerance
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Linagliptin

    once a day

    Drug: Linagliptin

  • Placebo comparator
    Placebo

    once a day

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. HbA1c Change From Baseline at Week 24

    Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

    Time frame: Baseline and at week 24

Secondary outcomes

  1. HbA1c Change From Baseline at Week 6

    Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

    Time frame: Baseline and at week 6

  2. HbA1c Change From Baseline at Week 12

    Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

    Time frame: Baseline and at week 12

  3. HbA1c Change From Baseline at Week 18

    Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

    Time frame: Baseline and at week 18

  4. HbA1c Change From Baseline at Week 24 in the Subset of Chinese Patients

    Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

    Time frame: Baseline and at week 24

  5. FPG Change From Baseline at Week 6

    Means are treatment adjusted for baseline fasting plasma glucose (FPG) and previous anti-diabetic medication.

    Time frame: Baseline and at week 6

  6. FPG Change From Baseline at Week 12

    Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.

    Time frame: Baseline and at week 12

  7. FPG Change From Baseline at Week 18

    Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.

    Time frame: Baseline and at week 18

  8. FPG Change From Baseline at Week 24

    Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.

    Time frame: Baseline and at week 24

  9. Number of Patients With HbA1c < 7.0%

    Number of patients with HbA1c \< 7.0% at week 24

    Time frame: baseline and at week 24

  10. Number of Patients With HbA1c < 7.0% at Week 24 With Baseline HbA1c >= 7.0%.

    Number of patients with HbA1c \< 7.0% at week 24 with baseline HbA1c \>= 7.0%.

    Time frame: baseline and at week 24

  11. Number of Patients With HbA1c < 6.5%

    Number of patients with HbA1c \< 6.5% at week 24

    Time frame: baseline and at week 24

  12. Number of Patients With HbA1c < 6.5% at Week 24 With Baseline HbA1c >= 6.5%.

    Number of patients with HbA1c \< 6.5% at week 24 with baseline HbA1c \>= 6.5%.

    Time frame: baseline and at week 24

  13. Number With HbA1c at Least Lowering 0.5%

    Number with HbA1c at least 0.5% lowering from baseline at week 24

    Time frame: baseline and at week 24

07

Results

Posted Jul 19, 2013

Participant flow

A total of 608 patients were screened in 19 centres in China, Malaysia,and Philippines.A total of 300 patients were randomised in a 1:2 ratio to receive either placebo (99 patients) or linagliptin 5 mg (201 patients).

Participant flow — Overall Study
MilestonePlaceboLinagliptin 5mg
Started99200
Completed87182
Not completed1218
Withdrew: Adverse event34
Withdrew: Protocol violation21
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject49
Withdrew: Lack of efficacy12
Withdrew: Patient's private reason11

Outcome measures

PrimaryHbA1c Change From Baseline at Week 24

Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

Time frame:
Baseline and at week 24
Reported as:
Least squares mean · % of HbA1c
HbA1c Change From Baseline at Week 24
% of HbA1cPlaceboLinagliptin 5mg
HbA1c Change From Baseline at Week 24-0.18 ± 0.10-0.68 ± 0.07
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.50 · 95% CI -0.71 to -0.28
SecondaryHbA1c Change From Baseline at Week 6

Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

Time frame:
Baseline and at week 6
Reported as:
Least squares mean · % of HbA1c
HbA1c Change From Baseline at Week 6
% of HbA1cPlaceboLinagliptin 5mg
HbA1c Change From Baseline at Week 6-0.072 ± 0.065-0.454 ± 0.049
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.383 · 95% CI -0.527 to -0.238
SecondaryHbA1c Change From Baseline at Week 12

Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

Time frame:
Baseline and at week 12
Reported as:
Least squares mean · % of HbA1c
HbA1c Change From Baseline at Week 12
% of HbA1cPlaceboLinagliptin 5mg
HbA1c Change From Baseline at Week 12-0.108 ± 0.08-0.609 ± 0.06
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.5 · 95% CI -0.677 to -0.323
SecondaryHbA1c Change From Baseline at Week 18

Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

Time frame:
Baseline and at week 18
Reported as:
Least squares mean · % of HbA1c
HbA1c Change From Baseline at Week 18
% of HbA1cPlaceboLinagliptin 5mg
HbA1c Change From Baseline at Week 18-0.159 ± 0.087-0.670 ± 0.066
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = <0.0001 · Adjusted mean difference: -0.512 · 95% CI -0.705 to -0.318
SecondaryHbA1c Change From Baseline at Week 24 in the Subset of Chinese Patients

Means are treatment adjusted for baseline HbA1c and previous anti-diabetic medication.

Time frame:
Baseline and at week 24
Reported as:
Least squares mean · % of HbA1c
HbA1c Change From Baseline at Week 24 in the Subset of Chinese Patients
% of HbA1cPlaceboLinagliptin 5mg
HbA1c Change From Baseline at Week 24 in the Subset of Chinese Patients-0.23 ± 0.11-0.69 ± 0.09
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = 0.0001 · Adjusted mean difference: -0.46 · 95% CI -0.69 to -0.23
SecondaryFPG Change From Baseline at Week 6

Means are treatment adjusted for baseline fasting plasma glucose (FPG) and previous anti-diabetic medication.

Time frame:
Baseline and at week 6
Reported as:
Least squares mean · mg/dL
FPG Change From Baseline at Week 6
mg/dLPlaceboLinagliptin 5mg
FPG Change From Baseline at Week 6-0.8 ± 2.7-12.0 ± 2.0
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = 0.0003 · Adjusted mean difference: -11.2 · 95% CI -17.2 to -5.2
SecondaryFPG Change From Baseline at Week 12

Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.

Time frame:
Baseline and at week 12
Reported as:
Least squares mean · mg/dL
FPG Change From Baseline at Week 12
mg/dLPlaceboLinagliptin 5mg
FPG Change From Baseline at Week 12-2.1 ± 3.0-11.0 ± 2.2
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = 0.0086 · Adjusted mean difference: -8.8 · 95% CI -15.4 to -2.3
SecondaryFPG Change From Baseline at Week 18

Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.

Time frame:
Baseline and at week 18
Reported as:
Least squares mean · mg/dL
FPG Change From Baseline at Week 18
mg/dLPlaceboLinagliptin 5mg
FPG Change From Baseline at Week 18-1.0 ± 3.4-10.5 ± 2.5
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = 0.0135 · Adjusted mean difference: -9.5 · 95% CI -17.0 to -2.0
SecondaryFPG Change From Baseline at Week 24

Means are treatment adjusted for baseline FPG and previous anti-diabetic medication.

Time frame:
Baseline and at week 24
Reported as:
Least squares mean · mg/dL
FPG Change From Baseline at Week 24
mg/dLPlaceboLinagliptin 5mg
FPG Change From Baseline at Week 241.5 ± 3.4-8.1 ± 2.5
Statistical analysis
  • Placebo vs Linagliptin 5mg · ANCOVA · p = 0.0113 · Adjusted mean difference: -9.6 · 95% CI -17.1 to -2.2
SecondaryNumber of Patients With HbA1c < 7.0%

Number of patients with HbA1c \< 7.0% at week 24

Time frame:
baseline and at week 24
Reported as:
Number · Patients
Number of Patients With HbA1c < 7.0%
PatientsPlaceboLinagliptin 5mg
Number of Patients With HbA1c < 7.0%2694
SecondaryNumber of Patients With HbA1c < 7.0% at Week 24 With Baseline HbA1c >= 7.0%.

Number of patients with HbA1c \< 7.0% at week 24 with baseline HbA1c \>= 7.0%.

Time frame:
baseline and at week 24
Reported as:
Number · Patients
Number of Patients With HbA1c < 7.0% at Week 24 With Baseline HbA1c >= 7.0%.
PatientsPlaceboLinagliptin 5mg
Number of Patients With HbA1c < 7.0% at Week 24 With Baseline HbA1c >= 7.0%.2380
Statistical analysis
  • Placebo vs Linagliptin 5mg · Regression, Logistic · p = 0.0021 · Odds ratio (or): 2.552 · 95% CI 1.407 to 4.629The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication
SecondaryNumber of Patients With HbA1c < 6.5%

Number of patients with HbA1c \< 6.5% at week 24

Time frame:
baseline and at week 24
Reported as:
Number · Patients
Number of Patients With HbA1c < 6.5%
PatientsPlaceboLinagliptin 5mg
Number of Patients With HbA1c < 6.5%1238
SecondaryNumber of Patients With HbA1c < 6.5% at Week 24 With Baseline HbA1c >= 6.5%.

Number of patients with HbA1c \< 6.5% at week 24 with baseline HbA1c \>= 6.5%.

Time frame:
baseline and at week 24
Reported as:
Number · Patients
Number of Patients With HbA1c < 6.5% at Week 24 With Baseline HbA1c >= 6.5%.
PatientsPlaceboLinagliptin 5mg
Number of Patients With HbA1c < 6.5% at Week 24 With Baseline HbA1c >= 6.5%.1136
Statistical analysis
  • Placebo vs Linagliptin 5mg · Regression, Logistic · p = 0.2500 · Odds ratio (or): 1.583 · 95% CI 0.724 to 3.46
SecondaryNumber With HbA1c at Least Lowering 0.5%

Number with HbA1c at least 0.5% lowering from baseline at week 24

Time frame:
baseline and at week 24
Reported as:
Number · Patients
Number With HbA1c at Least Lowering 0.5%
PatientsPlaceboLinagliptin 5mg
Number With HbA1c at Least Lowering 0.5%43128
Statistical analysis
  • Placebo vs Linagliptin 5mg · Regression, Logistic · p = 0.0005 · Odds ratio (or): 2.527 · 95% CI 1.494 to 4.276The odds-ratio is based on a logistic regression model including baseline HbA1c and previous antidiabetic medication

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/99 (2%)7/99 (7.1%)
Linagliptin 5mg—1/200 (0.5%)15/200 (7.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboLinagliptin 5mg
Acute coronary syndromeCardiac disorders1/990/200
Upper gastrointestinal haemorrhageGastrointestinal disorders1/990/200
Rotator cuff syndromeMusculoskeletal and connective tissue disorders1/990/200
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/991/200
Lumbar spinal stenosisMusculoskeletal and connective tissue disorders0/991/200
Most frequent other events
Most frequent other events
EventPlaceboLinagliptin 5mg
HyperlipidaemiaMetabolism and nutrition disorders3/9911/200
HyperglycaemiaMetabolism and nutrition disorders4/994/200

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboLinagliptin 5mgTotal
Mean54.1 ± 9.354.6 ± 10.154.4 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLinagliptin 5mgTotal
Female4084124
Male59116175
BMI
BMI(kg/m2)PlaceboLinagliptin 5mgTotal
Mean25.1 ± 3.425.5 ± 3.325.4 ± 3.4
Baseline HbA1c
Baseline HbA1c(%)PlaceboLinagliptin 5mgTotal
Mean8.09 ± 0.917.95 ± 0.897.99 ± 0.90
Baseline fasting plasma glucose
Baseline fasting plasma glucose(mg/dL)PlaceboLinagliptin 5mgTotal
Mean161.4 ± 39.9151.4 ± 32.4154.6 ± 35.2
08

Study locations

19 sites
  • 1218.66.86007 Boehringer Ingelheim Investigational Site
    Beijing, China
  • 1218.66.86011 Boehringer Ingelheim Investigational Site
    Chongqing, China
  • 1218.66.86008 Boehringer Ingelheim Investigational Site
    Dalian, China
  • 1218.66.86010 Boehringer Ingelheim Investigational Site
    Fuzhou, China
  • 1218.66.86014 Boehringer Ingelheim Investigational Site
    Hangzhou, China
  • 1218.66.86005 Boehringer Ingelheim Investigational Site
    Hefei, China
  • 1218.66.86006 Boehringer Ingelheim Investigational Site
    Hefei, China
  • 1218.66.86012 Boehringer Ingelheim Investigational Site
    Nanjing, China
  • 1218.66.86001 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1218.66.86002 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1218.66.86003 Boehringer Ingelheim Investigational Site
    Shanghai, China
  • 1218.66.86004 Boehringer Ingelheim Investigational Site
    Suzhou, China
  • 1218.66.86015 Boehringer Ingelheim Investigational Site
    Wenzhou, China
  • 1218.66.86009 Boehringer Ingelheim Investigational Site
    Wuhan, China
  • 1218.66.86013 Boehringer Ingelheim Investigational Site
    Yangzhou, China
  • 1218.66.60002 Boehringer Ingelheim Investigational Site
    Johor Bahru,, Malaysia
  • 1218.66.60001 Boehringer Ingelheim Investigational Site
    Kelantan, Malaysia
  • 1218.66.63001 Boehringer Ingelheim Investigational Site
    Marikina, Philippines
  • 1218.66.63002 Boehringer Ingelheim Investigational Site
    San Juan, Philippines
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010 and a primary completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2013, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2010
First posted
Oct 5, 2010
Start
Oct 2010
Primary completionActual
May 2012
Results first posted
Jul 19, 2013
Last update
Aug 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01214239
Responsible party
Sponsor
First posted
Oct 5, 2010
Start date
Oct 2010
Primary completion
May 2012
Results posted
Jul 19, 2013
Last update
Aug 25, 2016

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Linagliptin

Start the discussion